Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8626749rdf:typepubmed:Citationlld:pubmed
pubmed-article:8626749lifeskim:mentionsumls-concept:C0025519lld:lifeskim
pubmed-article:8626749lifeskim:mentionsumls-concept:C0431085lld:lifeskim
pubmed-article:8626749lifeskim:mentionsumls-concept:C0000610lld:lifeskim
pubmed-article:8626749lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8626749lifeskim:mentionsumls-concept:C1261322lld:lifeskim
pubmed-article:8626749lifeskim:mentionsumls-concept:C0024485lld:lifeskim
pubmed-article:8626749lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:8626749lifeskim:mentionsumls-concept:C1553628lld:lifeskim
pubmed-article:8626749pubmed:issue8lld:pubmed
pubmed-article:8626749pubmed:dateCreated1996-6-21lld:pubmed
pubmed-article:8626749pubmed:abstractTextThe effect of 6-aminonicotinamide on the metabolism of RIF-1 tumor cells was investigated using 13C and 31P NMR spectroscopy. 6-Aminonicotinamide can be metabolized to 6-amino-NAD(P), a competitive inhibitor of NAD(P)-requiring processes. 40 microM 6-aminonicotinamide led to an inhibition of 6-phosphogluconate dehydrogenase and an accumulation of 6-phosphogluconate. A subsequent accumulation of the 6-phosphogluconate precursor 6-phosphoglucono-delta-lactone was observed in the 13C NMR spectrum. These metabolites were shown to be intracellular, although a small amount of leakage of 6-phosphoglucono-delta-lactone occurred. The intracellular concentrations of 6-phosphogluconate and 6-phosphoglucono-delta-lactone were 1.9 +/- 0.8 micromol/108 cells (+/-1 standard deviation) and 0.8 +/- 0.4 micromol/10(8) cells, respectively, after 15 h. Glucose utilization and lactate production were significantly inhibited by 6-aminonicotinamide (both p < 0.05), indicating inhibition of glycolysis. 31P NMR data showed that phosphocreatine was significantly depleted in cells exposed to 6-aminonicotinamide (p < 0.05). Exposure of RIF-1 cells to 6-aminonicotinamide prior to 3- or 6-Gy x-irradiation induced a supra-additive cell kill, indicating that 6-aminonicotinamide is acting as a radiosensitizer. There was no effect of 6-aminonicotinamide alone or when the drug was given postradiation, suggesting that its mechanism of action may be by inhibition of radiation-induced repair.lld:pubmed
pubmed-article:8626749pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8626749pubmed:languageenglld:pubmed
pubmed-article:8626749pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8626749pubmed:citationSubsetIMlld:pubmed
pubmed-article:8626749pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8626749pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8626749pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8626749pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8626749pubmed:statusMEDLINElld:pubmed
pubmed-article:8626749pubmed:monthFeblld:pubmed
pubmed-article:8626749pubmed:issn0021-9258lld:pubmed
pubmed-article:8626749pubmed:authorpubmed-author:StreetJ CJClld:pubmed
pubmed-article:8626749pubmed:authorpubmed-author:AlfieriA AAAlld:pubmed
pubmed-article:8626749pubmed:authorpubmed-author:KoutcherJ AJAlld:pubmed
pubmed-article:8626749pubmed:authorpubmed-author:MahmoodUUlld:pubmed
pubmed-article:8626749pubmed:authorpubmed-author:BallonDDlld:pubmed
pubmed-article:8626749pubmed:issnTypePrintlld:pubmed
pubmed-article:8626749pubmed:day23lld:pubmed
pubmed-article:8626749pubmed:volume271lld:pubmed
pubmed-article:8626749pubmed:ownerNLMlld:pubmed
pubmed-article:8626749pubmed:authorsCompleteYlld:pubmed
pubmed-article:8626749pubmed:pagination4113-9lld:pubmed
pubmed-article:8626749pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:meshHeadingpubmed-meshheading:8626749-...lld:pubmed
pubmed-article:8626749pubmed:year1996lld:pubmed
pubmed-article:8626749pubmed:articleTitle13C and 31P NMR investigation of effect of 6-aminonicotinamide on metabolism of RIF-1 tumor cells in vitro.lld:pubmed
pubmed-article:8626749pubmed:affiliationDepartment of Medical Physics, Sloan-Kettering Cancer Center, New York, New York 10021, USA.lld:pubmed
pubmed-article:8626749pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8626749pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8626749lld:pubmed